Back to results
US 2005/0038007 A1Published application
Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
AssigneePfizer Inc.
InventorsWilliam Curatolo, Dwayne Friesen, Steven Sutton
Life of this patent
Estimating the term…
Abstract
A dosage form comprises a cholesteryl ester transfer protein inhibitor in a solubility-improved form and an HMG-CoA reductase inhibitor, wherein the dosage form provides immediate release of the HMG-CoA reductase inhibitor and controlled release of the cholesteryl ester transfer protein inhibitor.
Claims37
A dosage form comprising:
- (a) a cholesteryl ester transfer protein inhibitor in a solubility-improved form, and
- (b) an HMG-CoA reductase inhibitor;
- wherein said dosage form provides immediate release of said HMG-CoA reductase inhibitor and controlled release of said cholesteryl ester transfer protein inhibitor.
29 The dosage form of claim 24 wherein, following administration to an in vivo use environment, said dosage form provides a plasma concentration of said torcetrapib of about 70 ng/mL or more for a period of about 12 hr or more.
Dependencies are inferred from the claim text.